|
|
|
| Clinical effect of Pitavastatin Calcium Tablets combined with Aspirin in the treatment of coronary heart disease with hyperlipidemia |
| TONG Zao-ying |
| Department of Cardiology, Dexing People′s Hospital |
|
|
|
|
Abstract Objective To investigate the clinical effect of Pitavastatin Calcium Tablets combined with Aspirin in the treatment of coronary heart disease with hyperlipidemia. Methods Altogether 93 patients who had coronary heart disease with hyperlipidemia treated in Dexing People′s Hospital from March 2018 to February 2020 were selected as subjects and divided into control group (n=46) and observation group (n=47) according to the blind drawing method. The two groups were given conventional treatment, the control group was treated with Pitavastatin Calcium Tablets, while the observation group was treated with Aspirin on the basis of the control group. The clinical efficacy, blood lipid indexes and total incidence of adverse reactions were compared between the two groups. Results The clinical efficacy of the observation group was better than that of the control group, and the total effective rate of the observation group(97.87%) was higher than that of the control group (82.61%), with statistically significant differences (P<0.05). After treatment, the levels of total cholesterol (TC) ([1.56±0.37] mmol/L), triacylglycerol (TG) ([3.13±0.54] mmol/L), low density lipoprotein cholesterol (LDL-C) ([2.19±0.36] mmol/L) in the observation group were lower than those before treatment ([4.38±1.01], [6.49±1.52], [5.24±1.01] mmol/L), the differences were statistically significant (P<0.05). The levels of TC ([2.31±0.47] mmol/L), TG ([4.61±0.98] mmol/L), LDL-C ([3.28±0.49] mmol/L) in the control group after treatment were lower than those before treatment ([4.36±1.03], [6.51±1.48], [5.33±1.05] mmol/L), the differences were statistically significant (P<0.05). The high density lipoprotein cholesterol (HDL-C) of the observation group after treatment was(2.03±0.34) mmol/L, which was higher than that before treatment ([0.86±0.13] mmol/L), the HDL-C of the control group after treatment was (1.56±0.28) mmol/L, which was higher than that before treatment ([0.85±0.12] mmol/L), the differences were statistically significant (P<0.05). And the levels of TC, TG and LDL-C of the observation group after treatment were lower than those of the control group, the HDL-C level of the observation group was higher than that of the control group, the differences were statistically significant (P<0.05). There was no statistically significant difference in the total incidence of adverse reactions between the observation group (6.38%) and control group (13.04%) (P>0.05). Conclusion Pitavastatin Calcium Tablets combined with Aspirin has a significant effect in the treatment of coronary heart disease patients with hyperlipidemia, which can effectively improve patients′ blood lipid index, promote their physical recovery, and have high safety.
|
|
|
|
|
|
| [1] |
刘雅楠.不同他汀类用于冠心病并高胆固醇血症中患者血脂水平的变化及意义[J].当代医学，2020，29（7）：171-172.
|
| [2] |
郭丽娟，陆芳，扈晓霞，等.不同剂量瑞舒伐他汀钙对老年冠心病合并高脂血症患者的有效性和安全性分析[J].中华老年医学杂志，2019，38（5）：513-515.
|
| [3] |
中国心血管病风险评估和管理指南编写联合委员会.中国心血管病风险评估和管理指南[J].中华健康管理学杂志，2019，13（1）：7-26.
|
| [4] |
谭斌.阿托伐他汀钙片联合脂必泰治疗冠心病合并高脂血症的效果[J].当代医学，2020，29（3）：9-11.
|
| [5] |
沈正军.老年冠心病合并高脂血症应用瑞舒伐他汀钙治疗的疗效分析[J].中国医药导刊，2017，19（7）：729-730.
|
| [6] |
刘金发，林杰.匹伐他汀钙联合依折麦布治疗冠心病合并高脂血症的疗效及安全性观察[J].解放军预防医学杂志，2018，36（9）：23-26.
|
| [7] |
王艳，史玉红，李圣，等.氯吡格雷联合阿司匹林对冠心病心绞痛患者血清hs-CRP、TNF-α 及IL-6 水平的影响[J].现代生物医学进展，2017，17（2）：136-139.
|
| [8] |
陈平磊，陈文鑫，朱志侠.不同时间服用阿司匹林对非高血压冠心病病人血压变异性及清晨血压的影响[J].中西医结合心脑血管病杂志，2017，15（3）：101-103.
|
| [9] |
赵菊.分析匹伐他汀钙联合依折麦布治疗冠心病合并高脂血症的有效性、安全性[J].人人健康，2019，25（9）：243.
|
| [10] |
卢波，王晓静，王沙沙.匹伐他汀钙对症状性动脉粥样硬化颅内动脉狭窄患者的影响[J].中国病案，2018，19（11）：99-102.
|
| [11] |
刘金发，林杰.匹伐他汀钙联合依折麦布治疗冠心病合并高脂血症的疗效及安全性观察[J].解放军预防医学杂志，2018，36（9）：23-26.
|
| [12] |
慕杨娜，赵磊，于珊珊，等.国产匹伐他汀钙片在健康人体的生物等效性研究[J].山西医药杂志，2018，47（1）：3-6.
|
| [13] |
许宏磊.蒲参胶囊联合匹伐他汀治疗高脂血症的临床研究[J].现代药物与临床，2019，34（10）：2926-2930.
|
| [14] |
朱敏，石琳，王雯，等.匹伐他汀与阿托伐他汀对冠心病并非酒精性脂肪性肝病患者血脂代谢和肝功能影响的对比研究[J].实用心脑肺血管病杂志，2018，26（4）：71-73.
|
| [15] |
张玉蓉，高荣敏，陈家艺，等.匹伐他汀联合血必净注射液对急性冠脉综合征病人行PCI 术后疗效观察[J].内蒙古医科大学学报，2018，40（1）：50-54.
|
| [16] |
冯翔，姜睿，王少也，等.匹伐他汀与阿托伐他汀对冠状动脉旁路移植术后早期患者调节血脂的对比研究[J].心脏杂志，2018，30（4）：415-417.
|
| [17] |
王飞宇，赵小红，牟小引.综合护理干预在阿司匹林致冠心病患者上消化道出血治疗中的应用价值[J].现代消化及介入诊疗，2017，22（6）：895-897.
|
| [18] |
李大严，李小华，黎福理，等.复方丹参滴丸联合阿司匹林治疗冠心病的疗效及对患者血脂水平的影响[J].现代生物医学进展，2018，18（15）：164-167.
|
| [19] |
任桂晶，韩琳，秦少游，等.胶囊内镜在长期服用阿司匹林的冠心病患者中的诊断价值[J].中国实验诊断学，2018，22（7）：1271-1273.
|
| [20] |
杨艳敏.COMPASS 研究结果：利伐沙班联合阿司匹林成为冠心病抗栓治疗新选择[J].中华心律失常学杂志，2017，21（5）：459-460.
|
|
|
|
